Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186873 · ClinicalTrials.gov registry record · Phase 3
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
NCT02186873 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 208 participants.
The verdict
NCT02186873, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral joints).
Interventions
- DRUG Placebo
- DRUG Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2014-09-03 |
| Est. Completion | 2016-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186873
The ClinicalTrials.gov registry entry for NCT02186873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02186873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186873 about?
NCT02186873 is a clinical study titled "A Study of Golimumab in Participants With Active Ankylosing Spondylitis". The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac j...
What is the current status of trial NCT02186873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2014-09-03. Estimated completion is 2016-10-11.
What interventions are being tested in trial NCT02186873?
The interventions under investigation include: Placebo (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT02186873?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.